MedTrace Logo

Study of the Immune Response in Colon Adenocarcinoma

NCT03015038 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-12-10

No results posted yet for this study

Summary

Duration of each part of the study per patient:

* Screening: From 1 to 4 weeks
* Sampling period (blood and tissue): 1 day
* Follow-up by patient: 60 months
* Total study duration by patient: 84 months
* Total inclusion duration: 24 months
* Total Follow-up duration: 60 months
* Total study duration: 84 months

Conditions

  • Colon Adenocarcinoma

Sponsors & Collaborators

  • Innate Pharma

    collaborator INDUSTRY

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • Matthieu Allez, MD, PhD · Hopital Saint Louis

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-05
Primary Completion
2024-02-05
Completion
2024-02-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015038 on ClinicalTrials.gov